by Truveta staff | Sep 25, 2025 | Featured research, Research
Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most serious infections, often leading healthcare providers to start powerful, broad-spectrum antibiotics like intravenous (IV) vancomycin. While vancomycin can be life-saving, unnecessary use...
by Truveta staff | Sep 16, 2025 | Research
Continuous glucose monitoring (CGM) is increasingly recognized not only for its role in diabetes management but also for its potential impact on broader health outcomes. A recent consensus statement highlighted the need for additional evidence on CGM use in people...
by Truveta staff | Sep 15, 2025 | Research
Gestational diabetes is one of the most common complications of pregnancy, affecting roughly 5–9% of pregnancies in the United States. When diagnosed and managed early, patients can avoid complications such as high birth weight, preterm delivery, or cesarean section....
by Truveta staff | Sep 12, 2025 | Research
Non–small cell lung cancer (NSCLC) accounts for about 85% of lung cancer cases and remains the leading cause of cancer death worldwide. While major advances in targeted therapies and immunotherapies have transformed care, gaps persist in biomarker testing, treatment...
by Truveta Research | Sep 5, 2025 | Research, Research Insights
In July 2025, following the CVS formulary change, 9.6% of patients on AOM tirzepatide switched to a different drug. This was more than a 16-fold increase compared with the average earlier in the year. Among AOM tirzepatide users who switched to a different GLP-1...
by Truveta Research | Sep 5, 2025 | Research, Research Insights
AOM tirzepatide prescriptions rates, which had been rising by an average of +0.06 percentage points per month (Jan 2024–Jun 2025), grew only +0.03 points from June to July 2025 after the CVS GLP-1 formulary change. In contrast, AOM semaglutide increased by +0.1 points...
